<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" nameag="viewport"/>
<title>309 Pharmacology Miq Series</title>
<script src="https://cdn.tailwindcss.com"></script>
<script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
<script src="https://cdn.jsdelivr.net/npm/canvas-confetti@1.6.0/dist/confetti.browser.min.js"></script>
<style>
        /* Custom styles for enhanced aesthetics and responsiveness */
        .option-btn {
            transition: all 0.3s ease;
            box-shadow: 0 2px 4px rgba(0, 0, 0, 0.1);
        }
        .option-btn:hover, .option-btn:active {
            transform: scale(1.02);
            box-shadow: 0 4px 8px rgba(0, 0, 0, 0.2);
        }
        .option-btn.selected {
            background-color: #3b82f6;
            color: white;
        }
        .marked {
            background-color: #fef08a;
        }
        .progress-bar {
            transition: width 0.5s ease-in-out;
            background: linear-gradient(to right, #3b82f6, #22c55e);
            box-shadow: 0 2px 4px rgba(0, 0, 0, 0.2);
            animation: pulse 2s infinite;
        }
        @keyframes pulse {
            0% { opacity: 1; }
            50% { opacity: 0.8; }
            100% { opacity: 1; }
        }
        .question-nav-btn, .result-nav-btn-grid {
            width: 40px;
            height: 40px;
            display: flex;
            align-items: center;
            justify-content: center;
            border-radius: 8px;
            font-size: 16px;
            touch-action: manipulation;
            transition: all 0.2s ease;
        }
        .question-nav-btn:hover, .question-nav-btn:active, .result-nav-btn-grid:hover, .result-nav-btn-grid:active {
            transform: scale(1.05);
        }
        .answered {
            background-color: #22c55e;
            color: white;
        }
        .unanswered {
            background-color: #e5e7eb;
        }
        .marked-nav {
            border: 2px solid #fef08a;
        }
        .video-container, .audio-container {
            display: none;
            position: relative;
        }
        .video-container.active, .audio-container.active {
            display: block;
            animation: fadeIn 0.5s ease-in;
        }
        @keyframes fadeIn {
            from { opacity: 0; }
            to { opacity: 1; }
        }
        .section-transition {
            transition: opacity 0.3s ease;
        }
        .section-transition.hidden {
            opacity: 0;
            pointer-events: none;
        }
        .result-nav {
            display: flex;
            justify-content: space-between;
            align-items: center;
            margin-top: 1rem;
        }
        .result-nav-btn {
            background-color: #4b5563;
            color: white;
            padding: 0.5rem 1rem;
            border-radius: 8px;
            transition: all 0.2s ease;
        }
        .result-nav-btn:hover, .result-nav-btn:active {
            background-color: #374151;
            transform: scale(1.05);
        }
        .result-nav-btn:disabled {
            background-color: #d1d5db;
            cursor: not-allowed;
        }
        .error-message {
            color: #dc2626;
            font-weight: bold;
            margin-top: 1rem;
        }
        /* Mobile-specific adjustments */
        @media (max-width: 640px) {
            .question-nav-btn, .result-nav-btn-grid {
                width: 38px;
                height: 38px;
                font-size: 14px;
            }
            .nav-panel, .results-nav-panel {
                width: 100%;
                max-width: 100%;
                overscroll-behavior: contain;
            }
            .option-btn {
                padding: 12px;
                font-size: 14px;
            }
            .header-text {
                font-size: 1.5rem;
            }
            .subheader-text {
                font-size: 0.875rem;
            }
            .button-group, .result-nav {
                flex-direction: column;
                gap: 0.5rem;
            }
            .result-nav-btn {
                width: 100%;
                text-align: center;
            }
        }
        /* Dark mode styles */
        .dark .bg-gray-100 {
            background-color: #1f2937;
        }
        .dark .bg-white {
            background-color: #374151;
        }
        .dark .text-gray-700 {
            color: #d1d5db;
        }
        .dark .text-gray-800 {
            color: #e5e7eb;
        }
        .dark .bg-gray-200 {
            background-color: #4b5563;
        }
        .dark .border {
            border-color: #4b5563;
        }
        .dark .bg-blue-500 {
            background-color: #2563eb;
        }
        .dark .hover\:bg-blue-600:hover {
            background-color: #1d4ed8;
        }
        .dark .bg-yellow-300 {
            background-color: #b45309;
            color: white;
        }
        .dark .hover\:bg-yellow-400:hover {
            background-color: #92400e;
        }
        .dark .bg-green-500 {
            background-color: #15803d;
        }
        .dark .hover\:bg-green-600:hover {
            background-color: #166534;
        }
        .dark .bg-gray-500 {
            background-color: #4b5563;
        }
        .dark .hover\:bg-gray-600:hover {
            background-color: #374151;
        }
        .dark .result-nav-btn, .dark .result-nav-btn-grid {
            background-color: #2563eb;
        }
        .dark .result-nav-btn:hover, .dark .result-nav-btn:active, .dark .result-nav-btn-grid:hover, .dark .result-nav-btn-grid:active {
            background-color: #1d4ed8;
        }
        .dark .result-nav-btn:disabled, .dark .result-nav-btn-grid:disabled {
            background-color: #4b5563;
        }
        .video-placeholder {
            width: 400px;
            height: 300px;
            background-color: #f0f0f0;
            display: flex;
            align-items: center;
            justify-content: center;
            cursor: pointer;
            margin-top: 10px;
            border-radius: 8px;
            border: 1px solid #ccc;
        }
        .play-icon {
            font-size: 40px;
            color: #007bff;
        }
        .video-loading {
            position: absolute;
            top: 50%;
            left: 50%;
            transform: translate(-50%, -50%);
            border: 4px solid #f3f3f3;
            border-top: 4px solid #3b82f6;
            border-radius: 50%;
            width: 40px;
            height: 40px;
            animation: spin 1s linear infinite;
        }
        @keyframes spin {
            0% { transform: translate(-50%, -50%) rotate(0deg); }
            100% { transform: translate(-50%, -50%) rotate(360deg); }
        }
    </style>

<script>
    // --- GEMINI AUTO-CAPTURE LISTENER ---
    // This function runs immediately after the quiz determines an answer is INCORRECT.
    function captureMistake(questionIndex, questionsData) {
        try {
            const item = questionsData[questionIndex];
            // Use the question text as a unique, stable identifier
            const uniqueId = 'srs_quiz_' + btoa(item.text.substring(0, 50)).replace(/=/g, ''); 

            // 1. Clean and simplify the explanation for storage
            let explanationText = item.explanation || item.correct_answer || "No explanation provided.";
            
            // Strip complex HTML (images, lists) and boilerplate text
            explanationText = explanationText.replace(/<img[^>]*>/g, "[IMAGE]").trim(); // Replace images with placeholder
            explanationText = explanationText.replace(/<p><strong>Ans\. [A-Z]\).*/i, "").trim(); // Remove the repeated Answer line
            explanationText = explanationText.replace(/<p><strong>Educational Objective:<\/strong>.*?<\/p>/gs, "").trim(); // Remove EO block
            explanationText = explanationText.replace(/@dams_new_robot/g, "");
            explanationText = explanationText.replace(/<\/?[^>]+(>|$)/g, " ").trim(); // Final strip of remaining tags

            // 2. Prepare card data
            const cardData = {
                text: item.text,
                answer: item.correct_answer,
                explanation: explanationText.substring(0, 500), // Keep explanations short
                nextReview: 0, // Due immediately
                reviews: 0,
                source: document.title.split('-')[0].trim() || 'Quiz'
            };

            // 3. Save to Local Storage (SRS Bank)
            localStorage.setItem(uniqueId, JSON.stringify(cardData));
            
            console.log(`üß† Captured Mistake #${questionIndex + 1} from ${document.title}`);

        } catch (e) {
            console.error("SRS Capture Failed:", e);
        }
    }
    // --- END GEMINI AUTO-CAPTURE LISTENER ---
</script>

</head>
<body class="bg-gray-100 font-sans transition-colors duration-300 min-h-screen overflow-y-auto">
<!-- Header Section -->
<header class="bg-blue-600 text-white p-4 shadow-lg">
<div class="container mx-auto">
<h1 class="text-2xl md:text-3xl font-bold header-text">309 Pharmacology Miq Series</h1>
<p class="mt-2 text-sm md:text-base subheader-text">
                20 Questions | 80 Total Marks | 30 min Duration | ~90.0 sec/question
            </p>
<button class="mt-2 bg-gray-200 text-gray-800 px-3 py-1 rounded-lg hover:bg-gray-300 transition dark:bg-gray-600 dark:text-white" id="theme-toggle">
                Toggle Dark Mode
            </button>
</div>
</header>
<!-- Instructions Section -->
<section class="container mx-auto p-4 md:p-6 section-transition" id="instructions">
<div class="bg-white rounded-lg shadow-md p-5 md:p-8 md:p-5 md:p-8 min-h-screen md:min-h-0 md:rounded-lg md:shadow-md rounded-none shadow-none flex flex-col justify-between">
<h2 class="text-xl font-semibold mb-4">Instructions</h2>
<ul class="list-disc list-inside space-y-2 text-gray-700">
<li>This test contains 20 multiple choice questions.</li>
<li>Each question has only one correct answer.</li>
<li>You will have 30 minutes to complete the test.</li>
<li>Click or tap on an option to select your answer.</li>
<li>Use the "Mark for Review" button to revisit questions.</li>
<li>Navigate using Previous/Next buttons or the Questions Navigation panel.</li>
<li>Click "Submit" to finish and view results.</li>
<li>The test will auto-submit when time runs out.</li>
</ul>
<div class="mt-6 flex space-x-4 button-group md:flex-row flex-col">
<button class="bg-blue-500 text-white px-6 py-2 rounded-lg hover:bg-blue-600 transition" id="start-test">Start Test</button>


</div>
<div class="error-message hidden" id="error-message"></div>
</div>
</section>
<!-- Quiz Section -->
<section class="container mx-auto p-4 md:p-6 hidden section-transition" id="quiz">
<div class="bg-white rounded-lg shadow-md p-5 md:p-8 md:p-5 md:p-8 min-h-screen md:min-h-0 md:rounded-lg md:shadow-md rounded-none shadow-none flex flex-col justify-between">
<!-- Progress Bar -->
<div class="w-full bg-gray-200 rounded-full h-3 mb-4">
<div class="progress-bar h-3 rounded-full" id="progress-bar" style="width: 0%"></div>
</div>
<!-- Question Header -->
<div class="flex flex-col md:flex-row justify-between items-center mb-4">
<h2 class="text-lg font-semibold" id="question-number">Question <span>1</span> of 20</h2>
<p class="text-lg font-semibold mt-2 md:mt-0" id="timer">Time Remaining: <span>00:00</span></p>
</div>
<!-- Question Content -->
<div class="mb-6" id="question-content">
<p class="text-gray-800 mb-4" id="question-text"></p>
<div class="flex flex-wrap gap-4 mb-4" id="question-images"></div>
<div class="space-y-3" id="options"></div>
</div>
<!-- Navigation Buttons -->
<div class="flex flex-col md:flex-row justify-between items-center gap-2 md:gap-4">
<button class="bg-gray-300 text-gray-700 px-4 py-2 rounded-lg hover:bg-gray-400 transition w-full md:w-auto" disabled="" id="previous-btn">Previous</button>
<button class="bg-yellow-300 text-gray-700 px-4 py-2 rounded-lg hover:bg-yellow-400 transition w-full md:w-auto" id="mark-review">Mark for Review</button>
<button class="bg-blue-500 text-white px-4 py-2 rounded-lg hover:bg-blue-600 transition w-full md:w-auto" id="next-btn">Next</button>
<button class="bg-gray-500 text-white px-4 py-2 rounded-lg hover:bg-gray-600 transition w-full md:w-auto" id="nav-toggle">Questions Navigation</button>
<button class="bg-green-500 text-white px-4 py-2 rounded-lg hover:bg-blue-600 transition w-full md:w-auto" id="submit-test">Submit Test</button>
</div>
</div>
</section>
<!-- Results Section -->
<section class="container mx-auto p-4 md:p-6 hidden section-transition" id="results">
<div class="bg-white rounded-lg shadow-md p-5 md:p-8 md:p-5 md:p-8 min-h-screen md:min-h-0 md:rounded-lg md:shadow-md rounded-none shadow-none flex flex-col justify-between">
<h2 class="text-2xl font-semibold mb-4">309 Pharmacology Miq Series - Results</h2>
<div class="grid grid-cols-1 md:grid-cols-2 gap-4 mb-6">
<p><strong>Correct:</strong> <span id="correct-count">0</span></p>
<p><strong>Wrong:</strong> <span id="wrong-count">0</span></p>
<p><strong>Unanswered:</strong> <span id="unanswered-count">0</span></p>
<p><strong>Marked for Review:</strong> <span id="marked-count">0</span></p>
</div>
<h3 class="text-lg font-semibold mb-4" id="result-question-number">Question <span>1</span> of 20</h3>
<div class="space-y-6" id="results-content"></div>
<div class="result-nav">
<button aria-label="Previous question result" class="result-nav-btn" disabled="" id="prev-result">Previous</button>
<button aria-label="Toggle results navigation panel" class="result-nav-btn" id="results-nav-toggle">Results Navigation</button>
<button aria-label="Next question result" class="result-nav-btn" id="next-result">Next</button>
</div>
<div class="mt-6 flex space-x-4 button-group md:flex-row flex-col">
<button class="bg-blue-500 text-white px-6 py-2 rounded-lg hover:bg-blue-600 transition" id="take-again">Take Again</button>
<button class="bg-gray-500 text-white px-6 py-2 rounded-lg hover:bg-gray-600 transition" id="review-test">Review Test</button>
</div>
</div>
</section>
<!-- Exit Confirmation Modal -->
<div class="fixed inset-0 bg-black bg-opacity-50 flex items-center justify-center hidden" id="exit-modal">
<div class="bg-white rounded-lg p-6 max-w-sm w-full">
<h2 class="text-xl font-semibold mb-4">Leave Test?</h2>
<p class="text-gray-700 mb-4">Your progress will be lost if you leave this page. Are you sure you want to exit?</p>
<div class="flex justify-end space-x-4">
<button class="bg-gray-300 text-gray-700 px-4 py-2 rounded-lg hover:bg-gray-400 transition" id="continue-test">No, Continue</button>
<button class="bg-red-500 text-white px-4 py-2 rounded-lg hover:bg-red-600 transition" id="exit-test">Yes, Exit</button>
</div>
</div>
</div>
<!-- Submit Confirmation Modal -->
<div class="fixed inset-0 bg-black bg-opacity-50 flex items-center justify-center hidden" id="submit-modal">
<div class="bg-white rounded-lg p-6 max-w-sm w-full">
<h2 class="text-xl font-semibold mb-4">Confirm Submission</h2>
<p class="text-gray-700 mb-2">You have attempted <span id="attempted-count">0</span> of 20 questions.</p>
<p class="text-gray-700 mb-4"><span id="unattempted-count">0</span> questions are unattempted.</p>
<div class="flex justify-end space-x-4">
<button class="bg-gray-300 text-gray-700 px-4 py-2 rounded-lg hover:bg-gray-400 transition" id="cancel-submit">Cancel</button>
<button class="bg-green-500 text-white px-4 py-2 rounded-lg hover:bg-green-600 transition" id="confirm-submit">Submit Test</button>
</div>
</div>
</div>
<!-- Quiz Navigation Panel -->
<div class="fixed inset-y-0 right-0 nav-panel bg-white shadow-lg p-4 hidden overflow-y-auto" id="nav-panel">
<h2 class="text-lg font-semibold mb-4">Questions Navigation</h2>
<div class="mb-4">
<select class="w-full p-2 border rounded-lg text-gray-700" id="nav-filter">
<option value="all">All Questions</option>
<option value="answered">Answered</option>
<option value="unanswered">Unanswered</option>
<option value="marked">Marked for Review</option>
</select>
</div>
<div class="grid grid-cols-5 gap-2 md:gap-3" id="nav-grid"></div>
<button class="mt-4 bg-gray-500 text-white px-4 py-2 rounded-lg hover:bg-gray-600 transition w-full" id="close-nav">Close</button>
</div>
<!-- Results Navigation Panel -->
<div class="fixed inset-y-0 right-0 results-nav-panel bg-white shadow-lg p-4 hidden overflow-y-auto" id="results-nav-panel">
<h2 class="text-lg font-semibold mb-4">Results Navigation</h2>
<div class="mb-4">
<select class="w-full p-2 border rounded-lg text-gray-700" id="results-nav-filter">
<option value="all">All Questions</option>
<option value="answered">Answered</option>
<option value="unanswered">Unanswered</option>
<option value="marked">Marked for Review</option>
</select>
</div>
<div class="grid grid-cols-5 gap-2 md:gap-3" id="results-nav-grid"></div>
<button class="mt-4 bg-gray-500 text-white px-4 py-2 rounded-lg hover:bg-gray-600 transition w-full" id="close-results-nav">Close</button>
</div>
<!-- JavaScript Logic -->
<script>
        // Enable debug mode for detailed logging
        const DEBUG_MODE = true;

        // Log debug messages
        function debugLog(message) {
            if (DEBUG_MODE) {
                console.log(`[DEBUG] ${message}`);
            }
        }

        // Initialize questions with error handling
        let questions = [];
        let currentResultQuestion = 0; // State for current question in results
        try {
            debugLog("Attempting to parse questions_json");
            questions = [{"text": "A 72-year-old man with Parkinson‚Äôs disease presents for a routine follow-up. He reports improvement in his tremor and bradykinesia but is concerned about a recent development of a net-like purplish discoloration on his lower legs, which worsens in cold weather. He denies pain or itching. His medications include carbidopa-levodopa, pramipexole, and a recently added agent for dyskinesia control. Which of the following medications is MOST likely responsible for his skin changes?", "options": [{"label": "A", "text": "Amantadine", "correct": true}, {"label": "B", "text": "Levodopa", "correct": false}, {"label": "C", "text": "Pramipexole", "correct": false}, {"label": "D", "text": "Selegiline", "correct": false}], "correct_answer": "A. Amantadine", "question_images": [], "explanation_images": ["https://d2enu63wt1sf3u.cloudfront.net/ckfinder/files/1(1235).png"], "explanation": "<p><strong>Explanation:</strong></p>\n<ul><li>‚Ä¢ A. Amantadine ‚Äì Correct ‚Ä¢    Used in Parkinson‚Äôs disease for treatment of levodopa-induced dyskinesias. ‚Ä¢    Mechanism: NMDA receptor antagonist with dopaminergic effects. ‚Ä¢    Side Effect: Livedo reticularis is a unique and characteristic adverse effect. ‚Ä¢    Usually reversible upon discontinuation of the drug.</li><li>‚Ä¢ B. Levodopa ‚Ä¢    Mainstay treatment for Parkinson‚Äôs disease. ‚Ä¢    May cause motor fluctuations and dyskinesia, but does not cause livedo reticularis. ‚Ä¢    Skin reactions are rare.</li><li>‚Ä¢ C. Pramipexole ‚Ä¢    Dopamine agonist. ‚Ä¢    Can cause sleep attacks, impulse control disorders, and hypotension, but not associated with skin discoloration.</li><li>‚Ä¢ D. Selegiline ‚Ä¢    MAO-B inhibitor used as adjunct therapy. ‚Ä¢    May cause insomnia, nausea, and serotonin syndrome if combined improperly. ‚Ä¢    No association with livedo reticularis.</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Find out false statement", "options": [{"label": "A", "text": "Azithromycin associated with tendon rupture, particularly in older adults", "correct": true}, {"label": "B", "text": "Ciprofloxacin inhibits DNA gyrase and topoisomerase IV", "correct": false}, {"label": "C", "text": "Imipenem is resistant to beta-lactamase degradation", "correct": false}, {"label": "D", "text": "Linezolid is bacteriostatic", "correct": false}], "correct_answer": "A. Azithromycin associated with tendon rupture, particularly in older adults", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Explanation:</strong></p>\n<ul><li>‚Ä¢ A. Azithromycin is associated with tendon rupture ‚Äî FALSE ‚Ä¢    Azithromycin is a macrolide antibiotic, mainly associated with: o    QT prolongation o    GI upset ‚Ä¢    It does NOT cause tendon rupture. ‚Ä¢    Tendon rupture is a known side effect of fluoroquinolones (like ciprofloxacin), especially in older adults and those on corticosteroids.</li><li>‚Ä¢ B. Ciprofloxacin inhibits DNA gyrase and topoisomerase IV ‚Äî TRUE ‚Ä¢    Ciprofloxacin, a fluoroquinolone, targets: o    DNA gyrase in Gram-negative bacteria o    Topoisomerase IV in Gram-positive bacteria ‚Ä¢    This disrupts bacterial DNA replication and transcription ‚Äî bactericidal effect</li><li>‚Ä¢ C. Imipenem is resistant to beta-lactamase degradation ‚Äî TRUE ‚Ä¢    Imipenem is a carbapenem antibiotic. ‚Ä¢    It is broad-spectrum and resistant to most Œ≤-lactamases (except metallo-Œ≤-lactamases). ‚Ä¢    Often used with cilastatin to inhibit renal degradation.</li><li>‚Ä¢ D. Linezolid is bacteriostatic ‚Äî TRUE ‚Ä¢    Linezolid is an oxazolidinone antibiotic. ‚Ä¢    Inhibits the initiation of bacterial protein synthesis (binds 50S subunit). ‚Ä¢    Bacteriostatic against most organisms (except bactericidal for streptococci). ‚Ä¢    Used for MRSA, VRE, and drug-resistant Gram-positives</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Which of the following anti-helminthic drugs causes neuromuscular blockade leading to worm spastic paralysis?", "options": [{"label": "A", "text": "Albendazole", "correct": false}, {"label": "B", "text": "Ivermectin", "correct": false}, {"label": "C", "text": "Praziquantel", "correct": false}, {"label": "D", "text": "Pyrantel pamoate", "correct": true}], "correct_answer": "D. Pyrantel pamoate", "question_images": [], "explanation_images": ["https://d2enu63wt1sf3u.cloudfront.net/ckfinder/files/2(1006).png"], "explanation": "<p><strong>Explanation:</strong></p>\n<ul><li>‚Ä¢ Why the Other Options Are Incorrect:</li><li>‚Ä¢ A. Albendazole ‚Ä¢    Mechanism: Inhibits microtubule polymerization by binding Œ≤-tubulin. ‚Ä¢    Disrupts cellular transport and glucose uptake ‚Üí energy depletion ‚Üí death. ‚Ä¢    Used for broad-spectrum helminthic infections (e.g., neurocysticercosis, echinococcus). ‚Ä¢    No neuromuscular action.</li><li>‚Ä¢ B. Ivermectin ‚Ä¢    Mechanism: Binds to glutamate-gated chloride channels, leading to paralysis by hyperpolarization of nerve and muscle cells. ‚Ä¢    Used for strongyloidiasis and onchocerciasis (river blindness). ‚Ä¢    Though it leads to paralysis, it‚Äôs not via nicotinic blockade and thus different from pyrantel‚Äôs neuromuscular blockade.</li><li>‚Ä¢ C. Praziquantel ‚Ä¢    Mechanism: Increases membrane permeability to calcium, causing tetanic contraction and paralysis of flukes and tapeworms. ‚Ä¢    Used mainly for schistosomiasis and cestode (tapeworm) infections. ‚Ä¢    Acts via calcium influx, not neuromuscular blockade.</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A patient with schizophrenia presents to the ED with high fever, lead-pipe rigidity, and elevated CK levels. Which drug is most likely responsible?", "options": [{"label": "A", "text": "Clozapine", "correct": false}, {"label": "B", "text": "Aripiprazole", "correct": false}, {"label": "C", "text": "Risperidone", "correct": true}, {"label": "D", "text": "Quetiapine", "correct": false}], "correct_answer": "C. Risperidone", "question_images": [], "explanation_images": ["https://d2enu63wt1sf3u.cloudfront.net/ckfinder/files/3(879).png"], "explanation": "<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 62-year-old woman with a history of diabetes presents with a painful, vesicular rash distributed along the right thoracic dermatome. Which of the following is the most appropriate antiviral therapy?", "options": [{"label": "A", "text": "Acyclovir", "correct": true}, {"label": "B", "text": "Oseltamivir", "correct": false}, {"label": "C", "text": "Ribavirin", "correct": false}, {"label": "D", "text": "Tecovirimat", "correct": false}], "correct_answer": "A. Acyclovir", "question_images": ["https://d2enu63wt1sf3u.cloudfront.net/ckfinder/files/4(796).png"], "explanation_images": [], "explanation": "<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 45-year-old man on an antidepressant for major depression presents with myoclonus, hyperreflexia, and agitation. He was recently started on linezolid for an infection. What drug useful for treating these symptoms?", "options": [{"label": "A", "text": "Vilazodone", "correct": false}, {"label": "B", "text": "Fluoxetine", "correct": false}, {"label": "C", "text": "Cyproheptadine", "correct": true}, {"label": "D", "text": "Amitriptyline", "correct": false}], "correct_answer": "C. Cyproheptadine", "question_images": [], "explanation_images": [], "explanation": "<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Find out the true statements A. Phenobarbital is the first-line drug for treating seizures in neonates B. lacosamide enhances fast inactivation of voltage-gated sodium channels C. Ethosuximide is prescribed an antiepileptic for absence seizures with myoclonic jerk D. Cannabidiol useful in Dravet syndrome E. Oxcarbazepine has less risk of SIADH than carbamazepine", "options": [{"label": "A", "text": "A, B & C", "correct": false}, {"label": "B", "text": "B, C & D", "correct": false}, {"label": "C", "text": "A & E", "correct": false}, {"label": "D", "text": "A & D", "correct": true}], "correct_answer": "D. A & D", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Explanation:</strong></p>\n<ul><li>‚Ä¢ Phenobarbital is widely accepted as the first-line treatment for neonatal seizures. It enhances GABA-A receptor activity, leading to neuronal inhibition. Despite sedative effects, it is effective in immature brains where GABA can still have depolarizing effects.</li><li>‚Ä¢ Lacosamide enhances slow inactivation of voltage-gated sodium channels, not fast inactivation.</li><li>‚Ä¢ Ethosuximide is first-line for pure absence seizures, but not for myoclonic jerks.</li><li>‚Ä¢ In absence with myoclonus (e.g., juvenile myoclonic epilepsy), valproic acid is preferred.</li><li>‚Ä¢ Cannabidiol (CBD) is approved for Dravet syndrome, a rare and severe form of childhood epilepsy. It reduces seizure frequency and is used as adjunctive therapy.  Cannabidiol also approved for Lennox-Gastaut Syndrome and Tuberous Sclerosis Complex (TSC).</li><li>‚Ä¢ Oxcarbazepine is actually more associated with hyponatremia and SIADH than carbamazepine, especially in elderly patients. Monitoring sodium is essential.</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Which of the following is the most appropriate antidote for cyanide poisoning?", "options": [{"label": "A", "text": "N-acetylcysteine", "correct": false}, {"label": "B", "text": "Hydroxocobalamin", "correct": true}, {"label": "C", "text": "Flumazenil", "correct": false}, {"label": "D", "text": "Amyl nitrite", "correct": false}], "correct_answer": "B. Hydroxocobalamin", "question_images": [], "explanation_images": ["https://d2enu63wt1sf3u.cloudfront.net/ckfinder/files/5(755).png"], "explanation": "<p><strong>Explanation:</strong></p>\n<ul><li>‚Ä¢ Antidote: Hydroxocobalamin ‚Ä¢    Mechanism: Binds cyanide to form cyanocobalamin (vitamin B12), which is excreted in the urine. ‚Ä¢    Advantages: o    Acts rapidly o    Does not lower blood pressure (unlike nitrites) o    Preferred in smoke inhalation victims, where coexisting carbon monoxide poisoning is a risk Key Point: Hydroxocobalamin is the first-line treatment for cyanide poisoning, especially in emergency and prehospital settings.</li><li>‚Ä¢ Why the Other Options Are Incorrect:</li><li>‚Ä¢ A. N-acetylcysteine (NAC) ‚Ä¢    Used for: Acetaminophen (paracetamol) toxicity ‚Ä¢    Mechanism: Replenishes glutathione stores to detoxify NAPQI ‚Ä¢    No role in cyanide poisoning</li><li>‚Ä¢ C. Flumazenil ‚Ä¢    Used for: Benzodiazepine overdose ‚Ä¢    Mechanism: GABA-A receptor antagonist ‚Ä¢    Dangerous if mixed drug ingestion (can cause seizures) ‚Ä¢    Not relevant to cyanide toxicity</li><li>‚Ä¢ D. Amyl nitrite ‚Ä¢    Was part of an older cyanide antidote kit ‚Ä¢    Mechanism: Induces methemoglobinemia, which binds cyanide, forming cyanmethemoglobin ‚Ä¢    However, this reduces oxygen-carrying capacity and can worsen hypoxia, especially in smoke inhalation victims ‚Ä¢    No longer first-line; used only when hydroxocobalamin is unavailable</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Which of the following reactions is a Phase I metabolic transformation that typically introduces a polar functional group?", "options": [{"label": "A", "text": "Glucuronidation", "correct": false}, {"label": "B", "text": "Sulfation", "correct": false}, {"label": "C", "text": "Hydroxylation", "correct": true}, {"label": "D", "text": "Acetylation", "correct": false}], "correct_answer": "C. Hydroxylation", "question_images": [], "explanation_images": [], "explanation": "<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Which monoclonal antibody binds VEGF-A, inhibiting angiogenesis in metastatic cancers?", "options": [{"label": "A", "text": "Trastuzumab", "correct": false}, {"label": "B", "text": "Bevacizumab", "correct": true}, {"label": "C", "text": "Cetuximab", "correct": false}, {"label": "D", "text": "Rituximab", "correct": false}], "correct_answer": "B. Bevacizumab", "question_images": [], "explanation_images": ["https://d2enu63wt1sf3u.cloudfront.net/ckfinder/files/6(634).png"], "explanation": "<p><strong>Explanation:</strong></p>\n<ul><li>‚Ä¢ A. Trastuzumab ‚Ä¢    Target: HER2/neu receptor (ERBB2) ‚Ä¢    Use: HER2-positive breast cancer and gastric cancer ‚Ä¢    Mechanism: Inhibits proliferation of HER2-overexpressing cells ‚Ä¢    Does NOT bind VEGF-A</li><li>‚Ä¢ C. Cetuximab ‚Ä¢    Target: Epidermal Growth Factor Receptor (EGFR) ‚Ä¢    Use: Colorectal cancer (KRAS wild-type), head and neck squamous cell carcinoma ‚Ä¢    Mechanism: Blocks EGFR signaling, inhibiting cell proliferation ‚Ä¢    Does NOT inhibit angiogenesis via VEGF-A</li><li>‚Ä¢ D. Rituximab ‚Ä¢    Target: CD20 antigen on B cells ‚Ä¢    Use: o    Non-Hodgkin lymphoma o    Chronic lymphocytic leukemia (CLL) o    Rheumatoid arthritis o    ANCA-associated vasculitis ‚Ä¢    Mechanism: B-cell depletion ‚Ä¢    Unrelated to VEGF or angiogenesis</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Which agent causes maximum risk of hand-foot syndrome?", "options": [{"label": "A", "text": "Capecitabine", "correct": true}, {"label": "B", "text": "5-Fluorouracil", "correct": false}, {"label": "C", "text": "Methotrexate", "correct": false}, {"label": "D", "text": "Cytarabine", "correct": false}], "correct_answer": "A. Capecitabine", "question_images": [], "explanation_images": ["https://d2enu63wt1sf3u.cloudfront.net/ckfinder/files/7(560).png"], "explanation": "<p><strong>Explanation:</strong></p>\n<ul><li>‚Ä¢ A. Capecitabine ‚Äì Correct ‚Ä¢    Class: Oral prodrug of 5-Fluorouracil (5-FU) ‚Ä¢    Mechanism: Converted to 5-FU in the body, inhibiting thymidylate synthase ‚Üí DNA synthesis inhibition ‚Ä¢    Unique Feature: o    Has high and prolonged exposure in skin tissues, especially hands and feet. o    Causes dose-limiting and more frequent hand-foot syndrome compared to IV 5-FU. ‚Ä¢    Clinical Use: Breast cancer, colorectal cancer, gastric cancer ‚Ä¢    Management: o    Dose reduction or interruption o    Emollients, urea cream, cooling, and sometimes pyridoxine (though evidence is limited)</li><li>‚Ä¢ B. 5-Fluorouracil (5-FU) ‚Ä¢    Also causes hand-foot syndrome but less frequently and less severely than capecitabine. ‚Ä¢    IV 5-FU is less concentrated in peripheral tissues, leading to lower risk.</li><li>‚Ä¢ C. Methotrexate ‚Ä¢    Folate antagonist; used in cancer, autoimmune diseases, and ectopic pregnancy ‚Ä¢    Common toxicities: mucositis, hepatotoxicity, myelosuppression ‚Ä¢    Not typically associated with hand-foot syndrome</li><li>‚Ä¢ D. Cytarabine ‚Ä¢    Antimetabolite used mainly in acute leukemias ‚Ä¢    Common toxicities: cerebellar toxicity, myelosuppression, chemical conjunctivitis ‚Ä¢    Hand-foot syndrome is rare with this drug</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Which of the following drugs is approved for use in chronic Immune Thrombocytopenia (ITP) refractory to first-line therapies?", "options": [{"label": "A", "text": "Fostamatinib", "correct": true}, {"label": "B", "text": "Oprelvikin", "correct": false}, {"label": "C", "text": "Abciximab", "correct": false}, {"label": "D", "text": "Eltrombopag", "correct": false}], "correct_answer": "A. Fostamatinib", "question_images": [], "explanation_images": [], "explanation": "<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Which agent is used in rheumatoid arthritis and acts by inhibiting dihydroorotate dehydrogenase, blocking pyrimidine synthesis?", "options": [{"label": "A", "text": "Leflunomide", "correct": true}, {"label": "B", "text": "Methotrexate", "correct": false}, {"label": "C", "text": "Azathioprine", "correct": false}, {"label": "D", "text": "Hydroxychloroquine", "correct": false}], "correct_answer": "A. Leflunomide", "question_images": [], "explanation_images": ["https://d2enu63wt1sf3u.cloudfront.net/ckfinder/files/8(522).png"], "explanation": "<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Which of the following drugs targets the Œ±4Œ≤7 integrin and is useful in the treatment of Crohn‚Äôs disease?", "options": [{"label": "A", "text": "Aprepitant", "correct": false}, {"label": "B", "text": "Vedolizumab", "correct": true}, {"label": "C", "text": "Natalizumab", "correct": false}, {"label": "D", "text": "Ustekinumab", "correct": false}], "correct_answer": "B. Vedolizumab", "question_images": [], "explanation_images": ["https://d2enu63wt1sf3u.cloudfront.net/ckfinder/files/9(481).png"], "explanation": "<p><strong>Explanation:</strong></p>\n<ul><li>‚Ä¢ A. Aprepitant ‚Äì Incorrect ‚Ä¢    Class: Neurokinin-1 (NK1) receptor antagonist ‚Ä¢    Use: Primarily used to prevent chemotherapy-induced nausea and vomiting. ‚Ä¢    Not involved in the treatment of inflammatory bowel disease.</li><li>‚Ä¢ C. Natalizumab ‚Äì Incorrect ‚Ä¢    Mechanism: Targets Œ±4-integrin, but not selectively for Œ±4Œ≤7. ‚Ä¢    Use: Approved for multiple sclerosis and Crohn‚Äôs disease, but associated with progressive multifocal leukoencephalopathy (PML) due to JC virus reactivation. ‚Ä¢    Less gut-specific than Vedolizumab, and therefore has more systemic immunosuppressive risks.</li><li>‚Ä¢ D. Ustekinumab ‚Äì Incorrect ‚Ä¢    Mechanism: Monoclonal antibody against interleukin-12 and interleukin-23. ‚Ä¢    Use: Approved for Crohn‚Äôs disease, ulcerative colitis, psoriasis, and psoriatic arthritis. ‚Ä¢    While it is effective for Crohn‚Äôs disease, it does not target Œ±4Œ≤7 integrin.</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "What is the primary target of inclisiran, a novel lipid-lowering agent?", "options": [{"label": "A", "text": "Citrate lyase", "correct": false}, {"label": "B", "text": "Niemann-Pick C1-Like 1 (NPC1L1)", "correct": false}, {"label": "C", "text": "Microsomal TG transfer protein", "correct": false}, {"label": "D", "text": "PCSK9 mRNA via siRNA", "correct": true}], "correct_answer": "D. PCSK9 mRNA via siRNA", "question_images": [], "explanation_images": ["https://d2enu63wt1sf3u.cloudfront.net/ckfinder/files/10(428).png"], "explanation": "<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A patient with HFrEF on full-dose ARNI therapy continues to have high resting HR. Which drug reduces HR without affecting contractility or BP?", "options": [{"label": "A", "text": "Bisoprolol", "correct": false}, {"label": "B", "text": "Ivabradine", "correct": true}, {"label": "C", "text": "Verapamil", "correct": false}, {"label": "D", "text": "Amiodarone", "correct": false}], "correct_answer": "B. Ivabradine", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Explanation:</strong></p>\n<ul><li>‚Ä¢ B. Ivabradine ‚Äì Correct Answer ‚Ä¢    Mechanism: Selective inhibitor of the funny current (If) in the sinoatrial node. ‚Ä¢    Effect: Slows heart rate without affecting: o    Myocardial contractility o    Blood pressure ‚Ä¢    Indication: o    Symptomatic HFrEF (EF ‚â§35%) o    Sinus rhythm o    Resting heart rate ‚â•70 bpm o    Despite maximally tolerated beta-blocker or if beta-blockers are contraindicated ‚Ä¢    Unique Feature: Does not depress myocardial function or lower systemic BP, making it especially useful in patients with low BP or borderline EF.</li><li>‚Ä¢ A. Bisoprolol ‚Äì Incorrect ‚Ä¢    Beta-1 selective blocker, part of guideline-directed therapy for HFrEF. ‚Ä¢    Reduces HR and BP, and negatively affects contractility initially. ‚Ä¢    May not be tolerated in patients with already low blood pressure or severe HF symptoms.</li><li>‚Ä¢ C. Verapamil ‚Äì Incorrect ‚Ä¢    Non-dihydropyridine calcium channel blocker ‚Ä¢    Reduces HR, BP, and negatively inotropic (decreases contractility). ‚Ä¢    Contraindicated in HFrEF due to risk of worsening heart failure.</li><li>‚Ä¢ D. Amiodarone ‚Äì Incorrect ‚Ä¢    Primarily an antiarrhythmic; does have rate-slowing effects. ‚Ä¢    Has complex effects: blocks sodium, potassium, and calcium channels and beta-adrenergic receptors. ‚Ä¢    Not a first-line rate control agent in HFrEF for sinus tachycardia. ‚Ä¢    Significant toxicity (pulmonary, hepatic, thyroid) with chronic use.</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Which of the following DIURETIC is used in pseudotumor cerebri (idiopathic intracranial hypertension)?", "options": [{"label": "A", "text": "Acetazolamide", "correct": true}, {"label": "B", "text": "Amiloride", "correct": false}, {"label": "C", "text": "Mannitol", "correct": false}, {"label": "D", "text": "Furosemide", "correct": false}], "correct_answer": "A. Acetazolamide", "question_images": [], "explanation_images": ["https://d2enu63wt1sf3u.cloudfront.net/ckfinder/files/11(374).png"], "explanation": "<p><strong>Explanation:</strong></p>\n<ul><li>‚Ä¢ A. Acetazolamide ‚Äì Correct ‚Ä¢    Class: Carbonic anhydrase inhibitor ‚Ä¢    Mechanism: o    Inhibits carbonic anhydrase in the choroid plexus, reducing cerebrospinal fluid (CSF) production o    Also acts in the proximal tubule of the nephron ‚Ä¢    Effect: Lowers intracranial pressure by decreasing CSF volume ‚Ä¢    First-line treatment for pseudotumor cerebri</li><li>‚Ä¢ Why the Other Options Are Incorrect:</li><li>‚Ä¢ B. Amiloride ‚Ä¢    Potassium-sparing diuretic; blocks ENaC in the collecting duct ‚Ä¢    No effect on CSF production or ICP ‚Ä¢    Not used in pseudotumor cerebri</li><li>‚Ä¢ C. Mannitol ‚Ä¢    Osmotic diuretic ‚Ä¢    Used in acute management of intracranial hypertension (e.g., head trauma), but not suitable for chronic idiopathic intracranial hypertension ‚Ä¢    Works by drawing fluid out of brain parenchyma, but not used long-term</li><li>‚Ä¢ D. Furosemide ‚Ä¢    Loop diuretic; inhibits Na‚Å∫/K‚Å∫/2Cl‚Åª cotransporter in the loop of Henle ‚Ä¢    Occasionally used adjunctively, but not first-line ‚Ä¢    Does not significantly reduce CSF production</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Regarding Ranolazine, all of the following are true EXCEPT:", "options": [{"label": "A", "text": "Reduces cardiac fatty acid oxidation and stimulates glucose metabolism", "correct": false}, {"label": "B", "text": "It has weak Œ≤ receptor blocking activity", "correct": false}, {"label": "C", "text": "It blocks late sodium channels", "correct": false}, {"label": "D", "text": "Produces QT prolongation with significant torsades de pointes", "correct": true}], "correct_answer": "D. Produces QT prolongation with significant torsades de pointes", "question_images": [], "explanation_images": ["https://d2enu63wt1sf3u.cloudfront.net/ckfinder/files/12(364).png"], "explanation": "<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 56-year-old diabetic patient with NYHA Class III heart failure is started on a new oral anti-diabetic medication. Two weeks later, he presents with weight gain and worsening peripheral edema. Which of the following medications is MOST likely responsible?", "options": [{"label": "A", "text": "Dapagliflozin", "correct": false}, {"label": "B", "text": "Glimepiride", "correct": false}, {"label": "C", "text": "Pioglitazone", "correct": true}, {"label": "D", "text": "Sitagliptin", "correct": false}], "correct_answer": "C. Pioglitazone", "question_images": [], "explanation_images": ["https://d2enu63wt1sf3u.cloudfront.net/ckfinder/files/13(324).png"], "explanation": "<p><strong>Explanation:</strong></p>\n<ul><li>‚Ä¢ C. Pioglitazone ‚Äì Correct Answer ‚Ä¢    Class: Thiazolidinedione (TZD) ‚Ä¢    Mechanism: Activates PPAR-Œ≥ receptors, increasing insulin sensitivity in adipose tissue, liver, and skeletal muscle. ‚Ä¢    Adverse Effects: o    Fluid retention o    Weight gain o    Peripheral edema o    Can worsen heart failure, particularly NYHA Class III and IV ‚Ä¢    Contraindication: Avoid in symptomatic heart failure due to risk of volume overload and edema.</li><li>‚Ä¢ A. Dapagliflozin ‚Ä¢    Class: SGLT2 inhibitor ‚Ä¢    Mechanism: Promotes renal glucose excretion ‚Ä¢    Effects: o    Weight loss o    Reduction in heart failure hospitalizations o    Diuretic-like effect (mild natriuresis) ‚Ä¢    Important: Dapagliflozin is beneficial in patients with HFrEF and reduces fluid overload, not causes it.</li><li>‚Ä¢ B. Glimepiride ‚Ä¢    Class: Sulfonylurea ‚Ä¢    Mechanism: Stimulates insulin secretion from pancreatic Œ≤-cells ‚Ä¢    Adverse Effects: o    Hypoglycemia o    Weight gain ‚Ä¢    Does not typically cause edema or worsen heart failure.</li><li>‚Ä¢ D. Sitagliptin ‚Ä¢    Class: DPP-4 inhibitor ‚Ä¢    Mechanism: Increases endogenous GLP-1 levels ‚Üí enhances insulin release and decreases glucagon ‚Ä¢    Generally weight-neutral ‚Ä¢    Minimal risk of edema ‚Ä¢    Some agents in this class (e.g., saxagliptin) have been associated with HF risk, but sitagliptin itself is not clearly linked to worsening HF or edema.</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 68-year-old man, 3 days post-TURP, reports lower abdominal fullness and inability to void. He is stable, with a distended bladder and post-void residual of 550 mL on ultrasound. Neurologic exam is normal, and catheterization drains clear urine. Which cholinergic agent is most appropriate to stimulate bladder emptying?", "options": [{"label": "A", "text": "Bethanechol", "correct": true}, {"label": "B", "text": "Physostigmine", "correct": false}, {"label": "C", "text": "Carbachol", "correct": false}, {"label": "D", "text": "Donepezil", "correct": false}], "correct_answer": "A. Bethanechol", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Explanation:</strong></p>\n<ul><li>‚Ä¢ Why Bethanechol? ‚Ä¢    Mechanism: Direct muscarinic receptor agonist (primarily M3) ‚Üí activates bladder smooth muscle. ‚Ä¢    Use: Indicated for non-obstructive urinary retention and neurogenic bladder. ‚Ä¢    Promotes bladder contraction and facilitates micturition.</li><li>‚Ä¢ Why the Other Options Are Wrong: ‚Ä¢    B. Physostigmine: o    Indirect cholinergic agonist (reversible AChE inhibitor), crosses BBB ‚Üí mostly CNS effects. o    Used to reverse anticholinergic toxicity, not to stimulate bladder directly. ‚Ä¢    C. Carbachol: o    Potent cholinergic agonist with both muscarinic and nicotinic activity, mostly used topically in glaucoma. o    Not suitable systemically due to risk of uncontrolled cholinergic effects. ‚Ä¢    D. Donepezil: o    Centrally acting AChE inhibitor, used in Alzheimer‚Äôs disease. o    No role in treating bladder dysfunction or stimulating peripheral M3 receptors.</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}];
            if (!Array.isArray(questions) || questions.length === 0) {
                throw new Error("Questions data is empty or invalid");
            }
            debugLog(`Successfully parsed ${questions.length} questions`);
        } catch (e) {
            console.error("Failed to parse questions_json:", e);
            document.getElementById(